Traditional MedicarePrior AuthMedium impact
Jevtana® (cabazitaxel) (Revised)
Humana·FL, KY, SC, VA · Oncology·Medicaid
We identified it
Jul 22, 2026
Summary
This is a revised Prior Authorization policy for Jevtana® (cabazitaxel) affecting Medicare and four state Medicaid programs (Florida, Kentucky, South Carolina, Virginia). The policy update supersedes previous guidance; billing teams must verify current authorization requirements before processing claims for this cancer treatment drug.
Action Required
Immediately: Billing team must access the complete policy document at https://dctm.humana.com/Mentor/Web/v.aspx?objectID=090009298a586806 to obtain specific prior authorization requirements, approved indications, and documentation requirements for Jevtana® (cabazitaxel). Update billing system rules and provider alerts to reflect the revised policy. Ensure all claims for cabazitaxel in affected plans and states include required prior authorization before submission. Communicate policy changes to oncology providers and infusion centers. Claims submitted without proper prior authorization per revised policy will be denied.